Vincristine Sulfate

Retinoblastoma, Ovarian germ cell tumour, Choriocarcinoma + 17 more
Treatment
12 FDA approvals
20 Active Studies for Vincristine Sulfate

What is Vincristine Sulfate

VincristineThe Generic name of this drug
Treatment SummaryVincristine is a medication used to treat certain types of cancers, including leukemia, lymphoma, and Hodgkin’s disease. It is also known under the brand names Marqibo and Vincasar. Vincristine works by killing cancer cells, but does not cause significant bone marrow suppression at recommended doses. It is often used as part of a combination cancer treatment and can cause neuropathy as a side effect.
Vincasar PFSis the brand name
Vincristine Sulfate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vincasar PFS
Vincristine
2000
5

Approved as Treatment by the FDA

Vincristine, also known as Vincasar PFS, is approved by the FDA for 12 uses like Wilms' tumor and Neuroblastoma (NB) .
Wilms' tumor
Neuroblastoma (NB)
Acute Lymphoblastic Leukemia (ALL)
Lymphoma, Hodgkins
Rhabdomyosarcomas
Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin's Lymphoma
Neoplasms
Neuroblastoma
Acute Lymphoblastic Leukemia
Hodgkin's Lymphoma
Rhabdomyosarcoma

Effectiveness

How Vincristine Sulfate Affects PatientsVincristine is a medicine used to treat different types of cancer such as breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. It was first discovered in 1959 when scientists found that extracts from the periwinkle plant could help fight tumors. Vincristine works by attaching to the proteins of the cells and stopping them from dividing, which either kills the cells or stops them from multiplying. Vincristine also weakens the immune system. It only affects cells that are in certain parts of their life cycle.
How Vincristine Sulfate works in the bodyVincristine is used to fight cancer by preventing cells from dividing. It does this by blocking the movement of tubulin, a protein that helps control the division process. Vincristine may also affect the metabolism of certain molecules, the movement of calcium ions, cellular respiration, and the production of lipids and nucleic acids.

When to interrupt dosage

The dosage of Vincristine Sulfate is contingent upon the diagnosed condition, including Kaposi Sarcoma, Neoplasms and Small Cell Lung Cancer. The measure of dosage also differs depending on the technique of delivery (e.g. Liquid or Injection, solution - Intravenous) as featured in the table hereunder.
Condition
Dosage
Administration
Precursor Cell Lymphoblastic Leukemia-Lymphoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Retinoblastoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Ovarian germ cell tumour
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Choriocarcinoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Neoplasms
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Sarcoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Non-Hodgkin's Lymphoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
advanced Thymoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Hepatoblastoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Acute Lymphoblastic Leukemia
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Chronic Lymphocytic Leukemia
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Rhabdomyosarcoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Small Cell Lung Cancer
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Multiple Myeloma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Hodgkin's Lymphoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Neuroblastoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Acquired Immunodeficiency Syndrome
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Kaposi Sarcoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Gestational Trophoblastic Disease
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous
Pheochromocytoma
, 1.0 mg/mL, 5.0 mg, 5.0 mg/mL
, Injection, solution - Intravenous, Injection, solution, Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Kit, Kit - Intravenous

Warnings

Vincristine Sulfate Contraindications
Condition
Risk Level
Notes
Charcot-Marie-Tooth Disease
Do Not Combine
intrathecal administration
Do Not Combine
Demyelination
Do Not Combine
There are 20 known major drug interactions with Vincristine Sulfate.
Common Vincristine Sulfate Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Vincristine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Vincristine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Vincristine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Vincristine is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Vincristine is combined with Aldosterone.
Vincristine Sulfate Toxicity & Overdose RiskIntravenous administration of Marqibo® can be fatal in doses of 1300mg/kg in rats or 5.2mg/kg in mice. The dosing for Marqibo® is different from regular vincristine sulphate injection, so extra caution must be taken to avoid an overdose. The most common side effect of vincristine is neurotoxicity.

Vincristine Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Vincristine Sulfate?

At present, 531 active studies are investigating the potential of Vincristine Sulfate to treat Non-Hodgkin's Lymphoma, Hepatoblastomas and Retinoblastoma.
Condition
Clinical Trials
Trial Phases
Chronic Lymphocytic Leukemia
142 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4
Non-Hodgkin's Lymphoma
114 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4
Sarcoma
1 Actively Recruiting
Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Neoplasms
0 Actively Recruiting
Kaposi Sarcoma
7 Actively Recruiting
Phase 1, Phase 2
Neuroblastoma
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
4 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Retinoblastoma
5 Actively Recruiting
Phase 2, Phase 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1 Actively Recruiting
Phase 1, Phase 2
advanced Thymoma
0 Actively Recruiting
Gestational Trophoblastic Disease
1 Actively Recruiting
Phase 2
Small Cell Lung Cancer
50 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1
Hodgkin's Lymphoma
63 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Choriocarcinoma
2 Actively Recruiting
Phase 3, Phase 2
Ovarian germ cell tumour
5 Actively Recruiting
Not Applicable, Phase 2, Phase 1
Pheochromocytoma
0 Actively Recruiting
Rhabdomyosarcoma
0 Actively Recruiting
Acute Lymphoblastic Leukemia
118 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Hepatoblastoma
0 Actively Recruiting

Patient Q&A Section about vincristine sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the long term side effects of vincristine?

"If you keep taking the medication, you might experience neuritic pain and later have trouble with motor skills. People have also reported losing deep-tendon reflexes, being unable to lift their foot or wrist, problems with balance, and paralysis after taking the medication for a long time."

Answered by AI

What is the most common side effect of vincristine?

"The most common side effects of vincristine sulfate injections are nausea, vomiting, weight loss, diarrhea, bloating, stomach/abdominal pain or cramps, mouth sores, dizziness, headache, hair loss, constipation, loss of appetite, changes in sense of taste, and numbness and tingling in the hands and feet."

Answered by AI

Is vincristine sulfate a chemotherapy?

"chemotherapy that is used to treat various types of cancer."

Answered by AI

What is vincristine sulfate used for?

"A drug that can be used to treat acute leukemia independently, or in addition to other drugs treating Hodgkin lymphoma, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. It is being researched for further applications in treating other types of cancer."

Answered by AI

Clinical Trials for Vincristine Sulfate

Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Phase 1
Waitlist Available
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)Paolo Caimi, MDIncyte Corporation
Image of University of California, San Diego in La Jolla, United States.

SB-4826 for Non-Hodgkin's Lymphoma

18+
All Sexes
La Jolla, CA
The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lymphomas. The main questions this clinical trial aims to answer are: What is the maximum dose of SB-4826 that can be used safely in patients with solid tumors and non-Hodgkin lymphomas, and will it work? How does SB-4826 work in people with cancer? How is SB-4826 absorbed, broken down, and excreted by the body? Participants will: Take drug SB-4826 every other day for up to 1 year; keep a diary of when they take SB-4826 at home; visit the clinic for checkups, tests, and fill out study questionnaires.
Phase 1 & 2
Waitlist Available
University of California, San DiegoPeter Vu, MD
Have you considered Vincristine Sulfate clinical trials? We made a collection of clinical trials featuring Vincristine Sulfate, we think they might fit your search criteria.Go to Trials
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of City of Hope Medical Center in Duarte, United States.

Venetoclax + Obinutuzumab + Epcoritamab for Chronic Lymphocytic Leukemia

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Epcoritamab, a bispecific monoclonal antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. The combination of venetoclax and obinutuzumab is a standard treatment for CLL/SLL and has been found to be safe and effective. Adding epcoritamab to standard treatment with venetoclax and obinutuzumab may lead to deeper and longer-lasting responses in patients with untreated CLL/SLL.
Phase 2
Waitlist Available
City of Hope Medical Center (+6 Sites)Alexey V Danilov
Have you considered Vincristine Sulfate clinical trials? We made a collection of clinical trials featuring Vincristine Sulfate, we think they might fit your search criteria.Go to Trials
Have you considered Vincristine Sulfate clinical trials? We made a collection of clinical trials featuring Vincristine Sulfate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security